Advertisement

---

SORRENTO THERAPEUTICS, INC.

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia

[2013-07-01] -


Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit

[2013-06-24] -


Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Basel, Switzerland

[2013-06-21] -


Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology

[2013-06-06] -


Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City

[2013-05-30] -


Sorrento Therapeutics, Inc. and IGDRASOL present Phase I clinical data for the combination of CynviloqTM (paclitaxel polymeric micelle) plus gemcitabine for treatment of advanced pancreatic cancer at ASCO 2013 (booth #2090)

[2013-05-28] -


Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases

[2013-05-17] -


Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union

[2013-05-13] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers